Comparison of antiemetic effectiveness and safety of palonosetron and dexamethasone with palonosetron, dexamethasone and aprepitant in patients with lung cancer receiving combination therapy with carboplatin: A phase II randomized study
Not Applicable
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000010056
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe complications. Patients with brain metastasis. Patients with convulsive disorders requiring treatment. Patients with pleural effusion or ascites requiring treatment. Patients with gastrointestinal obstruction. Patients with drug sensitivities. Patients received antiemetic therapy as below, in the 24 hours before chemotherapy. 5HT3 receptor antagonist, NK1 receptor antagonist, adrenocortical steroid, antidopaminergic agent, phenothiazine derivative, antihistamine, benzodiazepine compound. Pregnant female, nursing mom.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method